The impact of pemafibrate on dyslipidemia in patients with severe adult growth hormone deficiency: A prospective cohort study.

The impact of pemafibrate on dyslipidemia in patients with severe adult growth hormone deficiency: A prospective cohort study. - The impact of pemafibrate on dyslipidemia in patients with severe adult growth hormone deficiency: A prospective cohort study.

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000038558

Enrollment

Registered

2019-11-12

Start date

2019-11-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

dyslipidemia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients with severe adult growth hormone deficiency under growth hormone replacement therapy who are treated in NTT east sapporo hospital or cooperated hospitals from date of IRB to December 2022 2)20 years of age or more 3)Patients with triglyceride level of 150 mg/dL or higher 4)Patients who are going to be treated with pemafibrate 5)Written informed consent

Exclusion criteria

Exclusion criteria: Patients who thought to be inappropriate to enter this study for some reasons by physician's judgments

Design outcomes

Primary

Measure	Time frame
Changes of TG before and after administration of pemafibrate	—

Secondary

Measure	Time frame
1)total lipid metabolism (HDL-cholesterol, RLP-cholesterol, etc) 2)Liver function 3)Renal function 4)Body weight, Body mass index, Abdominal circumference 5)Blood pressure 6)Adverse event 7)Influencing factors and changes on lipid metabolism, liver/renal function 8)The adult hypopituitarism questionnaire score	—

Countries

Japan

Contacts

Public Contactsou nagai

NTT EAST SAPPORO HOSPITAL Department of Diabetes and Endocrinology

sou.nagai@east.ntt.co.jp011-623-7000

Outcome results